<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 9.6.7908.23199 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 10/15/2021 11:08:13 AM -->
      <!-- iXBRL Library version: 1.0.7908.23207 -->
      <!-- iXBRL Service Job ID: 17822221-8133-411b-8a7e-0eb87e3cef3d -->

  <html xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:ampe="http://www.ampiopharma.com/20211011" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance"><head><meta http-equiv="content-type" content="text/html" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric contextRef="Duration_10_11_2021_To_10_11_2021_lxAuyC8CXU-Y8wWVALLlgQ" name="dei:EntityCentralIndexKey" id="Tc_hs3vh0K1yUiuruVEQPlZrg_2_1">0001411906</ix:nonNumeric><ix:nonNumeric contextRef="Duration_10_11_2021_To_10_11_2021_lxAuyC8CXU-Y8wWVALLlgQ" name="dei:AmendmentFlag" id="Tc_ThjJ7fRN3UaE4OodYTaLiw_3_1">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="ampe-20211011.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="Duration_10_11_2021_To_10_11_2021_lxAuyC8CXU-Y8wWVALLlgQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411906</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-11</xbrli:startDate><xbrli:endDate>2021-10-11</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;min-height:5.75pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:center;text-indent:0pt;border-bottom:1.0pt solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_ca0a89db_2a0f_41ab_8fb7_1589b08ce51f"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-size:18pt;font-weight:bold;">UNITED STATES<br />SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 5pt 0pt;"><b style="font-weight:bold;">Washington, D.C. 20549</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:1.0pt;margin-bottom:5pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:100%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:18pt;text-align:center;text-indent:0pt;margin:0pt 0pt 5pt 0pt;"><b style="font-weight:bold;">FORM </b><ix:nonNumeric contextRef="Duration_10_11_2021_To_10_11_2021_lxAuyC8CXU-Y8wWVALLlgQ" name="dei:DocumentType" id="Narr_-yrE0QgzaUWENkv4SzRDVQ"><b style="font-weight:bold;">8-K</b></ix:nonNumeric></p><div style="font-family:'Times New Roman','Times','serif';font-size:1.0pt;margin-bottom:5pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:100%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">CURRENT REPORT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">PURSUANT TO SECTION&#160;13 OR 15(d)&#160;</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 5pt 0pt;"><b style="font-weight:bold;">OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 5pt 0pt;"><b style="font-weight:bold;">Date of Report (Date of earliest event reported): </b><ix:nonNumeric contextRef="Duration_10_11_2021_To_10_11_2021_lxAuyC8CXU-Y8wWVALLlgQ" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="Narr_vh1a7UJ4Dkq5nHG6oEad2A"><b style="font-weight:bold;">October 11, 2021</b></ix:nonNumeric></p><div style="font-family:'Times New Roman','Times','serif';font-size:1.0pt;margin-bottom:5pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:100%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:24pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_11_2021_To_10_11_2021_lxAuyC8CXU-Y8wWVALLlgQ" name="dei:EntityRegistrantName" id="Narr_9Fk-A_rogkaL6iGmRTJ5WA"><b style="font-weight:bold;">AMPIO PHARMACEUTICALS, INC.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 5pt 0pt;"><b style="font-weight:bold;">(Exact name of registrant as specified in its charter)</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:1.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:100%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_79514924_cfb6_493d_a1f5_0086496939a5"></a><a id="Tc_hWtIDJvNpEeUjeaeN69-3A_2_0"></a><a id="Tc_3_pfyP9Frkyd3yr7_udw8A_2_1"></a><a id="Tc_FC63nkAXzEOAs-sEwFUPIw_2_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.59%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:33.04%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:33.36%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:33.59%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 1pt 0pt;"><ix:nonNumeric contextRef="Duration_10_11_2021_To_10_11_2021_lxAuyC8CXU-Y8wWVALLlgQ" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="Tc_EN78hhjo_0qqWlihDbl-8A_1_0"><b style="font-weight:bold;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:33.04%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 1pt 0pt;"><ix:nonNumeric contextRef="Duration_10_11_2021_To_10_11_2021_lxAuyC8CXU-Y8wWVALLlgQ" name="dei:EntityFileNumber" id="Tc_NR5yGrs2fEK-lSmgpgI46Q_1_1"><b style="font-weight:bold;">001-35182</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:33.36%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 1pt 0pt;"><ix:nonNumeric contextRef="Duration_10_11_2021_To_10_11_2021_lxAuyC8CXU-Y8wWVALLlgQ" name="dei:EntityTaxIdentificationNumber" id="Tc_8VsYaDLCHkKBM5UdpxMn4A_1_2"><b style="font-weight:bold;">26-0179592</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:33.59%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 1pt 0pt;"><b style="font-weight:bold;">(State or other jurisdiction of<br />incorporation)</b></p></td><td style="vertical-align:top;width:33.04%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 1pt 0pt;"><b style="font-weight:bold;">(Commission File Number)</b></p></td><td style="vertical-align:top;width:33.36%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 1pt 0pt;"><b style="font-weight:bold;">(IRS Employer Identification No.)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_11_2021_To_10_11_2021_lxAuyC8CXU-Y8wWVALLlgQ" name="dei:EntityAddressAddressLine1" id="Narr_kujK0DWPcEqeS2d2BKJgDQ"><b style="font-weight:bold;">373 Inverness Parkway, Suite 200</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_11_2021_To_10_11_2021_lxAuyC8CXU-Y8wWVALLlgQ" name="dei:EntityAddressCityOrTown" id="Narr_ZtR1eValrEimr6cG5DieYg"><b style="font-weight:bold;">Englewood</b></ix:nonNumeric><b style="font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_10_11_2021_To_10_11_2021_lxAuyC8CXU-Y8wWVALLlgQ" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="Narr_Hdx3G7FYW0S71s8-1wXsRA"><b style="font-weight:bold;">Colorado</b></ix:nonNumeric><b style="font-weight:bold;"> </b><ix:nonNumeric contextRef="Duration_10_11_2021_To_10_11_2021_lxAuyC8CXU-Y8wWVALLlgQ" name="dei:EntityAddressPostalZipCode" id="Narr_PmCtbFU7QEaW70BwT-lOEA"><b style="font-weight:bold;">80112</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 5pt 0pt;"><b style="font-weight:bold;">(Address of Principal Executive Offices) (Zip Code)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Registrant&#8217;s telephone number, including area code: (</b><ix:nonNumeric contextRef="Duration_10_11_2021_To_10_11_2021_lxAuyC8CXU-Y8wWVALLlgQ" name="dei:CityAreaCode" id="Narr__GpvjtHNyEGdvSOA2bdYZQ"><b style="font-weight:bold;">720</b></ix:nonNumeric><b style="font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_10_11_2021_To_10_11_2021_lxAuyC8CXU-Y8wWVALLlgQ" name="dei:LocalPhoneNumber" id="Narr_ejYZrYXWPUSK_3gPv3MNbA"><b style="font-weight:bold;">437-6500</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:7pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Not Applicable</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 5pt 0pt;"><b style="font-weight:bold;">(Former name, or former address, if changed since last report)</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:1.0pt;margin-bottom:5pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:100%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 5pt 0pt;">Check the appropriate box below if the Form&#160;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><ix:nonNumeric contextRef="Duration_10_11_2021_To_10_11_2021_lxAuyC8CXU-Y8wWVALLlgQ" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="Narr_1Obt6_otrkOZqpJUOa2ddA"><span style="font-family:'Segoe UI Symbol';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">&#9744;</span></ix:nonNumeric></span>Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><ix:nonNumeric contextRef="Duration_10_11_2021_To_10_11_2021_lxAuyC8CXU-Y8wWVALLlgQ" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="Narr_mJDZ_BdlrkCUTDiuyhEGxQ"><span style="font-family:'Segoe UI Symbol';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">&#9744;</span></ix:nonNumeric></span>Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><ix:nonNumeric contextRef="Duration_10_11_2021_To_10_11_2021_lxAuyC8CXU-Y8wWVALLlgQ" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="Narr_riIcBGwAyEaUNOVgPs1SNQ"><span style="font-family:'Segoe UI Symbol';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">&#9744;</span></ix:nonNumeric></span>Pre-commencement communications pursuant to Rule&#160;14d-2(b)&#160;under the Exchange Act (17 CFR 240.14d-2(b))</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><ix:nonNumeric contextRef="Duration_10_11_2021_To_10_11_2021_lxAuyC8CXU-Y8wWVALLlgQ" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="Narr_wBEMYUolB029Bu6beEmgFw"><span style="font-family:'Segoe UI Symbol';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">&#9744;</span></ix:nonNumeric></span>Pre-commencement communications pursuant to Rule&#160;13e-4(c)&#160;under the Exchange Act (17 CFR 240.13e-4(c))</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">Securities registered pursuant to Section 12(b) of the Act:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_8d10a49f_7efa_4e2d_926b_73f0a2da03d5"></a><a id="Tc_Vf3w76n42UqtCZA0OkPV0g_1_0"></a><a id="Tc_CeLPNUtGwEGvmSpKv_HHww_1_1"></a><a id="Tc_sIEjYn9ooEagiQ_RmELF6w_1_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:40.08%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:22.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:37.56%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:40.08%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.37;text-align:center;margin:0pt 0pt 2.2pt 0pt;">Title of each class</p></td><td style="vertical-align:top;width:22.34%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.37;text-align:center;margin:0pt 0pt 2.2pt 0pt;">Trading Symbol</p></td><td style="vertical-align:top;width:37.56%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.37;text-align:center;margin:0pt 0pt 2.2pt 0pt;">Name of each exchange on which registered</p></td></tr><tr><td style="vertical-align:top;width:40.08%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:center;margin:0pt 0pt 2.2pt 0pt;"><ix:nonNumeric contextRef="Duration_10_11_2021_To_10_11_2021_lxAuyC8CXU-Y8wWVALLlgQ" name="dei:Security12bTitle" id="Tc_o3rTIUulMUCVLUBdlf2nMg_2_0"><span style="font-size:9pt;">Common Stock, $0.0001 par value</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:22.34%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:center;margin:0pt 0pt 2.2pt 0pt;"><ix:nonNumeric contextRef="Duration_10_11_2021_To_10_11_2021_lxAuyC8CXU-Y8wWVALLlgQ" name="dei:TradingSymbol" id="Tc_84tEYOH2b0yMHntU3jTO_Q_2_1"><span style="font-size:9pt;">AMPE</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:37.56%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:center;margin:0pt 0pt 2.2pt 0pt;"><ix:nonNumeric contextRef="Duration_10_11_2021_To_10_11_2021_lxAuyC8CXU-Y8wWVALLlgQ" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="Tc_jTEnelDLL0CWf6GvqeYTWg_2_2"><span style="font-size:9pt;">NYSE American</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 5pt 0pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt 0pt 5pt 0pt;">Emerging growth company <ix:nonNumeric contextRef="Duration_10_11_2021_To_10_11_2021_lxAuyC8CXU-Y8wWVALLlgQ" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="Narr_bf4oQdqizUyyR3_xGWs4OA"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act. <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-indent:0pt;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;"><span style="font-family:'Segoe UI Symbol';font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;text-indent:0pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';font-size:0pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_1aa3ec3f_9ba0_4dd5_bd73_e01d78aff0d7"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;line-height:1.43;text-align:left;">Item 5.02</b></span><b style="font-weight:bold;">Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;text-indent:36pt;margin:9pt 0pt 9pt 0pt;"><span style="font-style:italic;font-weight:bold;">Appointment of Directors</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;text-indent:36pt;margin:9pt 0pt 9pt 0pt;"><span style="font-style:italic;font-weight:bold;">Mr. J. Kevin Buchi</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.41;text-align:justify;text-indent:32.4pt;margin:0pt 2.95pt 0pt 3pt;">On October 13, 2021, the Board of Directors (the <span style="font-style:italic;font-weight:bold;">&#8220;Board&#8221;</span>) of Ampio Pharmaceuticals, Inc. (the <span style="font-style:italic;font-weight:bold;">&#8220;Company&#8221;</span>) appointed Mr. J. Kevin Buchi to serve as a member of the Board. Mr. Buchi served as Chief Executive Officer and a director of Biospecifics Technologies Corp. (NASDAQ: BSTC) from October 2019 until April 2020. Mr. Buchi served as Impax Laboratories, LLC&#8217;s Interim President and Chief Executive Officer from December 2016 until March 2017 and as member of the Impax Board of Directors from November 2016 until the completion of the combination of Impax and Amneal Pharmaceuticals (NYSE: AMRX) in May 2018. Mr. Buchi served as President and Chief Executive Officer of TetraLogic Pharmaceuticals (formerly NASDAQ: TLOG) from August 2013 to December 2016. Before TetraLogic, he served as Corporate Vice President of Global Branded Products at Teva Pharmaceutical Industries Limited (NYSE: TEVA) from 2011 to May 2012. Mr. Buchi was Chief Executive Officer of Cephalon, Inc. (formerly NASDAQ: CEPH), which was acquired by Teva Pharmaceutical Industries Limited in October 2011. In addition, Mr. Buchi has served as an independent director of Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) since 2018 and Chairman of its Board of Directors since January 2019, and currently serves as a director of Amneal Pharmaceuticals Inc. (NYSE: AMRX) and Benitec Biopharma Ltd. (NASDAQ: BNTC). Mr. Buchi received his B.A. degree in Chemistry from Cornell University and a Masters of Management degree from the J.L. Kellogg Graduate School of Management, Northwestern University. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.41;text-align:justify;text-indent:32.4pt;margin:0pt 2.95pt 0pt 3pt;"><span style="margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;text-indent:36pt;margin:0pt;">There are no arrangements or understandings between Mr. Buchi and any other persons pursuant to which he was selected as a director, and he has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.41;text-align:justify;text-indent:32.4pt;margin:0pt 2.95pt 0pt 3pt;"><span style="font-style:italic;font-weight:bold;">Mr. Michael Martino</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.41;text-align:justify;text-indent:32.4pt;margin:0pt 2.95pt 0pt 3pt;"><span style="font-style:italic;font-weight:bold;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;text-indent:36pt;margin:0pt;"><span style="white-space:pre-wrap;">On October 13, 2021, the Board appointed Mr. Michael Martino to serve as a member of the Board. Mr. Martino has served as President, Chief Executive Officer and a director of HemaFlo Therapetuics Inc., a private company focused on the treatment of acute kidney injury, since January 2016. Prior to HemaFlow, Mr. Martino was President and Chief Executive Officer of Ambit Biosciences, a company focused on the development of a drug to treat acute myeloid leukemia, from November 2011 to November 2014. Under his leadership, Ambit initiated a large, multi-national Phase III study; secured $25 million in private financing; completed a $90 million initial public offering; and ultimately sold the company to a large, Japanese pharmaceutical company for $450 million in cash plus future milestone payments. Mr. Martino also previously served as President, Chief Executive Officer and a director of Arzeda, a synthetic biology company, and Sonus Pharmaceuticals, an oncology drug development company. In addition, Mr. Martino currently serves on the board of Caravan Biologix, a private company primarily focused on the development of novel oncology drugs, and was a founding director at Excision BioTherapeutics, Inc.  Mr. Martino has a BBA from Roanoke College, where he served as a Trustee from 2016 to 2020, and a MBA from Virginia Tech. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.43;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;text-indent:36pt;margin:0pt;">There are no arrangements or understandings between Mr. Martino and any other persons pursuant to which he was selected as a director, and he has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;text-indent:36pt;margin:0pt;"><span style="background-color:#ffffff;">For their service on the Board, Messrs. Buchi and Martino will receive the same cash compensation as other non-management directors, as described in the Company&#8217;s Definitive Proxy Statement on Schedule 14A, originally filed with the Securities and Exchange Commission (the </span><span style="background-color:#ffffff;font-style:italic;font-weight:bold;">&#8220;Commission&#8221;</span><span style="background-color:#ffffff;">) on June 30, 2021. In addition, each of Messrs. Buchi and Martino will receive an initial grant of 150,000 options to purchase shares of the Company&#8217;s common stock. Such </span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;margin:0pt;"><span style="background-color:#ffffff;white-space:pre-wrap;">options shall vest ratably on a monthly basis over a period of three years from the grant date.  In addition, it is expected that each of Messrs. Buchi and Martino will execute the Company&#8217;s standard form of indemnification agreement. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;text-indent:36pt;margin:0pt;"><span style="background-color:#ffffff;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;text-indent:36pt;margin:0pt;">Additional details regarding the above may be found in the press release attached as Exhibit 99.1 to this Current Report on Form 8-K, which is hereby incorporated by reference.<br /><span style="background-color:#ffffff;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;text-align:justify;margin:0pt 2.9pt 0pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></span><span style="font-style:italic;font-weight:bold;">Appointment of Officer</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;text-align:justify;margin:0pt 2.9pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.41;text-align:justify;text-indent:32.4pt;margin:0pt 2.95pt 0pt 3pt;">On October 13, 2021, the Board appointed Holli Cherevka, the Company&#8217;s Chief Operating Officer (<span style="font-style:italic;font-weight:bold;">&#8220;COO&#8221;</span>), to also serve as President of the Company. Ms. Cherevka, 38, has served as the Company&#8217;s COO since September 2017. &#160;Prior to taking her current role, Ms. Cherevka served as<i style="font-style:italic;"> </i>the Company&#8217;s Vice President of Operations and oversaw the clinical, regulatory, and manufacturing operations. Since starting at Ampio in January 2013, Ms. Cherevka has held the following additional roles of increasing responsibility: Director of Clinical Trials (from January 2013 to November 2013), Senior Director of Clinical Trials (from November 2013 to May 2015), Vice President of Operations (from May 2015 to September 2017) and COO (from September 2017 to current). Previously, Ms. Cherevka was the Director of Business Development at the American College of Radiology (ACR) Image Metrix from 2011 to 2013. Ms. Cherevka earned a B.A. degree from California State University, Chico, and an M.S. degree in biomedical and molecular sciences research from King&#8217;s College, London. Ms. Cherevka is a member of the Parenteral Drug Association, Colorado Bioscience Association and the International Society of Pharmaceutical Engineers, and a board member of the Professional Science Master&#8217;s in Biomedical Sciences (PSM) program at the University of Denver. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.41;text-align:justify;text-indent:32.4pt;margin:0pt 2.95pt 0pt 3pt;"><span style="margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;text-indent:36pt;margin:0pt;">Additional details regarding the above may be found in the press release attached as Exhibit 99.1 to this Current Report on Form 8-K, which is hereby incorporated by reference.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;text-indent:36pt;margin:0pt;">There are no arrangements or understandings between Ms. Cherevka and any other persons pursuant to which she was selected as the Company&#8217;s President. There are also no family relationships between Ms. Cherevka and any director or executive officer of the Company, and she has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">In connection with her appointment, the Company entered into a new three-year employment agreement with Ms. Cherevka (the <span style="font-style:italic;font-weight:bold;">&#8220;Cherevka Employment Agreement&#8221;</span><span style="white-space:pre-wrap;">), the terms of which are further described below.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.41;text-align:justify;text-indent:32.4pt;margin:0pt 2.95pt 0pt 3pt;"><span style="font-style:italic;font-weight:bold;">Amendment of Employment Agreements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.41;text-align:justify;text-indent:32.4pt;margin:0pt 2.95pt 0pt 3pt;"><span style="font-style:italic;font-weight:bold;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.33;text-align:justify;text-indent:32.4pt;margin:0pt 2.95pt 0pt 3pt;"><span style="font-style:italic;font-weight:bold;">Mr. Michael Macaluso</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.33;text-align:justify;text-indent:32.4pt;margin:0pt 2.95pt 0pt 3pt;"><span style="font-style:italic;font-weight:bold;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.33;text-align:justify;text-indent:32.4pt;margin:0pt 2.95pt 0pt 3pt;">On October 11, 2021, the Company entered into a new three-year employment agreement (the <span style="font-style:italic;font-weight:bold;">&#8220;Macaluso Employment Agreement&#8221;</span>) with Michael Macaluso, the Company&#8217;s Chief Executive Officer and principal executive officer. The Macaluso Employment Agreement supersedes and replaces the Company&#8217;s prior employment agreement with Mr. Macaluso entered into on December 14, 2019. The Macaluso Employment Agreement provides for an annual base salary of $550,000 and an annual discretionary bonus of up to fifty percent (50%) of Mr. Macaluso&#8217;s base salary, with the exact amount to be determined by the Compensation Committee of the Board based on achievement of individual and Company performance objectives established by the Compensation Committee. In connection with the Macaluso Employment Agreement, Mr. Macaluso was awarded 950,000 shares of restricted stock, with 150,000 shares vesting upon the effective date of the Macaluso Employment Agreement, 200,000 shares vesting on January 1, 2022 and 200,000 additional shares vesting annually each year thereafter, such that all shares of restricted stock will be fully vested on January 1, 2025. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.33;text-align:justify;text-indent:32.4pt;margin:0pt 2.95pt 0pt 3pt;"><span style="margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.33;text-align:justify;text-indent:32.4pt;margin:0pt 2.95pt 0pt 3pt;">If Mr. Macaluso&#8217;s employment is terminated by the Company without Cause (as defined in the Macaluso Employment Agreement) or by Mr. Macaluso for Good Reason (as defined in Macaluso Employment Agreement), he </p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.33;text-align:justify;margin:0pt 2.95pt 0pt 3pt;">will be entitled to a lump sum severance payment equal to six months of his base salary in effect at the date of termination, less applicable withholding. In addition, the vesting and exercisability of all then outstanding options held by Mr. Macaluso will accelerate in full. Upon the occurrence of a Change in Control (as defined in the Macaluso Employment Agreement), all then outstanding stock options, restricted stock and other stock-based grants held by Mr. Macaluso will immediately and irrevocably vest and become exercisable and any restrictions thereon shall lapse. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">This description of the Macaluso Employment Agreement does not purport to be complete and is subject to, and qualified in its entirety by, the full text of the Macaluso Employment Agreement, <span style="background-color:#ffffff;">which will be filed as an exhibit to the Company&#8217;s Annual Report on Form&#160;10-K for the year ended December 31, 2021.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.33;text-align:justify;text-indent:32.4pt;margin:0pt 2.95pt 0pt 3pt;"><span style="font-style:italic;font-weight:bold;">Ms. Holli Cherevka</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.33;text-align:justify;text-indent:32.4pt;margin:0pt 2.95pt 0pt 3pt;"><span style="font-style:italic;font-weight:bold;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.33;text-align:justify;text-indent:32.4pt;margin:0pt 2.95pt 0pt 3pt;">On October 11, 2021, the Company and Ms. Cherevka entered into the Cherevka Employment Agreement. The Cherevka Employment Agreement supersedes and replaces the Company&#8217;s prior employment agreement with Ms. Cherevka entered into on September 16, 2019. The Cherevka Employment Agreement provides that Ms. Cherevka will serve as the Company&#8217;s President and COO for an annual base salary of $375,000 and an annual discretionary bonus of up to fifty percent (50%) of Ms. Cherevka&#8217;s base salary, with the exact amount to be determined by the Compensation Committee of the Board based on achievement of individual and Company performance objectives established by the Compensation Committee. In connection with the Cherevka Employment Agreement, Ms. Cherevka was awarded 500,000 shares of restricted stock, with 100,000 shares vesting upon the effective date of the Cherevka Employment Agreement, 100,000 shares vesting on January 1, 2022 and 100,000 additional shares vesting annually each year thereafter, such that all shares of restricted stock will be fully vested on January 1, 2025. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.33;text-align:justify;text-indent:32.4pt;margin:0pt 2.95pt 0pt 3pt;"><span style="margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.33;text-align:justify;text-indent:32.4pt;margin:0pt 2.95pt 0pt 3pt;">If Ms. Cherevka&#8217;s employment is terminated by the Company without Cause (as defined in the Cherevka Employment Agreement) or by Ms. Cherevka for Good Reason (as defined in the Cherevka Employment Agreement), she will be entitled to a lump sum severance payment equal to six months of her base salary in effect at the date of termination, less applicable withholding. In addition, the vesting and exercisability of all then outstanding options held by Ms. Cherevka will accelerate in full. Upon the occurrence of a Change in Control (as defined in the Cherevka Employment Agreement), all then outstanding stock options, restricted stock and other stock-based grants held by Ms. Cherevka will immediately and irrevocably vest and become exercisable and any restrictions thereon shall lapse. </p><a id="page25"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">This description of the Cherevka Employment Agreement does not purport to be complete and is subject to, and qualified in its entirety by, the full text of the Cherevka Employment Agreement, <span style="background-color:#ffffff;">which will be filed as an exhibit to the Company&#8217;s Annual Report on Form&#160;10-K for the fiscal year ended December 31, 2021.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;margin:9pt 0pt 9pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span><span style="background-color:#ffffff;font-style:italic;font-weight:bold;">Mr. Daniel Stokely</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.33;text-align:justify;text-indent:32.4pt;margin:0pt 2.95pt 0pt 3pt;">On October 11, 2021, the Company entered into a new three-year employment agreement (the <span style="font-style:italic;font-weight:bold;">&#8220;Stokely Employment Agreement&#8221;</span>) with Daniel Stokely, the Company&#8217;s Chief Financial Officer and principal financial officer. The Stokely Employment Agreement supersedes and replaces the Company&#8217;s prior employment agreement with Mr. Stokely entered into on July 9, 2019. The Stokely Employment Agreement provides for an annual base salary of $335,000 and an annual discretionary bonus of up to fifty percent (50%) of Mr. Stokely&#8217;s base salary, with the exact amount to be determined by the Compensation Committee of the Board based on achievement of individual and Company performance objectives established by the Compensation Committee. In connection with the Stokely Employment Agreement, Mr. Stokely was awarded 335,000 shares of restricted stock, with 67,000 shares vesting upon the effective date of the Stokely Employment Agreement, 67,000 shares vesting on January 1, 2022 and 67,000 additional shares vesting annually each year thereafter, such that all shares of restricted stock will be fully vested on January 1, 2025. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.33;text-align:justify;text-indent:32.4pt;margin:0pt 2.95pt 0pt 3pt;"><span style="margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.33;text-align:justify;text-indent:32.4pt;margin:0pt 2.95pt 0pt 3pt;">If Mr. Stokely&#8217;s employment is terminated by the Company without Cause (as defined in the Stokely Employment Agreement) or by Mr. Stokely for Good Reason (as defined in the Stokely Employment Agreement), he will be entitled to a lump sum severance payment equal to six months of his base salary in effect at the date of termination, less applicable withholding. In addition, the vesting and exercisability of all then outstanding options held by Mr. Stokely </p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.33;text-align:justify;margin:0pt 2.95pt 0pt 3pt;">will accelerate in full. Upon the occurrence of a Change in Control (as defined in the Stokely Employment Agreement), all then outstanding stock options, restricted stock and other stock-based grants held by Mr. Stokely will immediately and irrevocably vest and become exercisable and any restrictions thereon shall lapse. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">This description of the Stokely Employment Agreement does not purport to be complete and is subject to, and qualified in its entirety by, the full text of the Stokely Employment Agreement, <span style="background-color:#ffffff;">which will be filed as an exhibit to the Company&#8217;s Annual Report on Form&#160;10-K for the fiscal year ended December 31, 2021.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;padding-bottom:9pt;text-indent:36pt;margin:9pt 0pt 0pt 0pt;"><span style="background-color:#ffffff;font-style:italic;font-weight:bold;">Adoption of Indemnification Agreement</span></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;text-align:justify;text-indent:36pt;margin:0pt;">On October 13, 2021, the Board approved and adopted an updated form of indemnification agreement to be entered into by the Company with its directors, executive officers and certain other key employees (the <span style="font-style:italic;font-weight:bold;">&#8220;Indemnification Agreement&#8221;</span>). The Indemnification Agreement was adopted in order to incorporate certain updates that reflect current market indemnification practices and will supersede any previous indemnification agreement entered into by the Company with the respective director, executive officer or other key employee.</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;text-align:justify;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;text-align:justify;text-indent:36pt;margin:0pt;">As is the case with the Company&#8217;s previous form of indemnification agreement, the Indemnification Agreement requires the Company to indemnify the counterparty, to the fullest extent permitted by law, for certain expenses, including attorneys&#8217; fees, judgments, penalties, fines and settlement amounts actually and reasonably incurred in any action or proceeding arising out of such party&#8217;s status as a service provider to the Company or one of its subsidiaries or any other company or enterprise to which service is provided at the Company&#8217;s request.</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;text-align:justify;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;text-align:justify;text-indent:36pt;margin:0pt;">The foregoing summary and description of the provisions of the Indemnification Agreement does not purport to be complete and is subject to, and qualified in its entirety by, the full text of the Indemnification Agreement, which will be filed as an exhibit to the Company&#8217;s Annual Report on Form&#160;10-K for the fiscal year ended December 31, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:89.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Item&#160;9.01</b></p></td><td style="vertical-align:top;width:89.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Financial Statements and Exhibits.</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;white-space:pre-wrap;">(d)    Exhibits.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">99.1</span></span><a style="-sec-extract:exhibit;" href="ampe-20211011xex99d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Press release, dated October 13, 2021</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">104</span></span>The cover page from this Current Report on Form 8-K, formatted in Inline XBRL. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_f815eced_84e9_4374_8040_b56cc78885b7"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SIGNATURES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:12pt 0pt 0pt 0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_9kMHG5YVt48867FT4rw"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:3.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:42.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:3.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:top;width:46.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">AMPIO PHARMACEUTICALS, INC. </b></p></td><td style="vertical-align:top;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:42.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date:&#160;&#160;October 15, 2021</p></td><td style="vertical-align:top;width:3.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:42.15%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 0pt 0pt 9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Daniel G. Stokely</p></td><td style="vertical-align:top;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:42.15%;margin:0pt;padding:0pt 0pt 0pt 9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name: Daniel G. Stokely</p></td><td style="vertical-align:top;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:42.15%;margin:0pt;padding:0pt 0pt 0pt 9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title: Chief Financial Officer and Secretary</p></td><td style="vertical-align:top;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Cambria Math';visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body></html>
[{"type": "8-K", "sequence": "1", "filename": "ampe-20211011x8k.htm", "description": "8-K", "secsgml_size_bytes": 58434}]
{"company-data": {"conformed-name": "Ampio Pharmaceuticals, Inc.", "cik": "0001411906", "assigned-sic": "2834", "irs-number": "260179592", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-35182", "film-number": "211324959"}, "business-address": {"street1": "373 INVERNESS PARKWAY", "street2": "SUITE 200", "city": "ENGLEWOOD", "state": "CO", "zip": "80112", "phone": "720-437-6500"}, "mail-address": {"street1": "373 INVERNESS PARKWAY", "street2": "SUITE 200", "city": "ENGLEWOOD", "state": "CO", "zip": "80112"}, "former-company": {"former-conformed-name": "Chay Enterprises, Inc.", "date-changed": "20070910"}}
​
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
October 11, 2021
AMPIO PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
​
​
​
​
Delaware
001-35182
26-0179592
(State or other jurisdiction of
incorporation)
(Commission File Number)
(IRS Employer Identification No.)
​
373 Inverness Parkway, Suite 200
Englewood
,
Colorado
80112
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code: (
720
)
437-6500
​
Not Applicable
(Former name, or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
​
Title of each class
Trading Symbol
Name of each exchange on which registered
Common Stock, $0.0001 par value
AMPE
NYSE American
​
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
☐
​
​
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Appointment of Directors
Mr. J. Kevin Buchi
On October 13, 2021, the Board of Directors (the
"Board"
) of Ampio Pharmaceuticals, Inc. (the
"Company"
) appointed Mr. J. Kevin Buchi to serve as a member of the Board. Mr. Buchi served as Chief Executive Officer and a director of Biospecifics Technologies Corp. (NASDAQ: BSTC) from October 2019 until April 2020. Mr. Buchi served as Impax Laboratories, LLC's Interim President and Chief Executive Officer from December 2016 until March 2017 and as member of the Impax Board of Directors from November 2016 until the completion of the combination of Impax and Amneal Pharmaceuticals (NYSE: AMRX) in May 2018. Mr. Buchi served as President and Chief Executive Officer of TetraLogic Pharmaceuticals (formerly NASDAQ: TLOG) from August 2013 to December 2016. Before TetraLogic, he served as Corporate Vice President of Global Branded Products at Teva Pharmaceutical Industries Limited (NYSE: TEVA) from 2011 to May 2012. Mr. Buchi was Chief Executive Officer of Cephalon, Inc. (formerly NASDAQ: CEPH), which was acquired by Teva Pharmaceutical Industries Limited in October 2011. In addition, Mr. Buchi has served as an independent director of Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) since 2018 and Chairman of its Board of Directors since January 2019, and currently serves as a director of Amneal Pharmaceuticals Inc. (NYSE: AMRX) and Benitec Biopharma Ltd. (NASDAQ: BNTC). Mr. Buchi received his B.A. degree in Chemistry from Cornell University and a Masters of Management degree from the J.L. Kellogg Graduate School of Management, Northwestern University.
​
There are no arrangements or understandings between Mr. Buchi and any other persons pursuant to which he was selected as a director, and he has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.
​
Mr. Michael Martino
​
On October 13, 2021, the Board appointed Mr. Michael Martino to serve as a member of the Board. Mr. Martino has served as President, Chief Executive Officer and a director of HemaFlo Therapetuics Inc., a private company focused on the treatment of acute kidney injury, since January 2016. Prior to HemaFlow, Mr. Martino was President and Chief Executive Officer of Ambit Biosciences, a company focused on the development of a drug to treat acute myeloid leukemia, from November 2011 to November 2014. Under his leadership, Ambit initiated a large, multi-national Phase III study; secured $25 million in private financing; completed a $90 million initial public offering; and ultimately sold the company to a large, Japanese pharmaceutical company for $450 million in cash plus future milestone payments. Mr. Martino also previously served as President, Chief Executive Officer and a director of Arzeda, a synthetic biology company, and Sonus Pharmaceuticals, an oncology drug development company. In addition, Mr. Martino currently serves on the board of Caravan Biologix, a private company primarily focused on the development of novel oncology drugs, and was a founding director at Excision BioTherapeutics, Inc.  Mr. Martino has a BBA from Roanoke College, where he served as a Trustee from 2016 to 2020, and a MBA from Virginia Tech.
​
There are no arrangements or understandings between Mr. Martino and any other persons pursuant to which he was selected as a director, and he has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.
​
For their service on the Board, Messrs. Buchi and Martino will receive the same cash compensation as other non-management directors, as described in the Company's Definitive Proxy Statement on Schedule 14A, originally filed with the Securities and Exchange Commission (the
"Commission"
) on June 30, 2021. In addition, each of Messrs. Buchi and Martino will receive an initial grant of 150,000 options to purchase shares of the Company's common stock. Such
options shall vest ratably on a monthly basis over a period of three years from the grant date.  In addition, it is expected that each of Messrs. Buchi and Martino will execute the Company's standard form of indemnification agreement.
​
Additional details regarding the above may be found in the press release attached as Exhibit 99.1 to this Current Report on Form 8-K, which is hereby incorporated by reference.
​
Appointment of Officer
​
On October 13, 2021, the Board appointed Holli Cherevka, the Company's Chief Operating Officer (
"COO"
), to also serve as President of the Company. Ms. Cherevka, 38, has served as the Company's COO since September 2017.  Prior to taking her current role, Ms. Cherevka served as
the Company's Vice President of Operations and oversaw the clinical, regulatory, and manufacturing operations. Since starting at Ampio in January 2013, Ms. Cherevka has held the following additional roles of increasing responsibility: Director of Clinical Trials (from January 2013 to November 2013), Senior Director of Clinical Trials (from November 2013 to May 2015), Vice President of Operations (from May 2015 to September 2017) and COO (from September 2017 to current). Previously, Ms. Cherevka was the Director of Business Development at the American College of Radiology (ACR) Image Metrix from 2011 to 2013. Ms. Cherevka earned a B.A. degree from California State University, Chico, and an M.S. degree in biomedical and molecular sciences research from King's College, London. Ms. Cherevka is a member of the Parenteral Drug Association, Colorado Bioscience Association and the International Society of Pharmaceutical Engineers, and a board member of the Professional Science Master's in Biomedical Sciences (PSM) program at the University of Denver.
​
Additional details regarding the above may be found in the press release attached as Exhibit 99.1 to this Current Report on Form 8-K, which is hereby incorporated by reference.
​
There are no arrangements or understandings between Ms. Cherevka and any other persons pursuant to which she was selected as the Company's President. There are also no family relationships between Ms. Cherevka and any director or executive officer of the Company, and she has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.
In connection with her appointment, the Company entered into a new three-year employment agreement with Ms. Cherevka (the
"Cherevka Employment Agreement"
), the terms of which are further described below.
Amendment of Employment Agreements
​
Mr. Michael Macaluso
​
On October 11, 2021, the Company entered into a new three-year employment agreement (the
"Macaluso Employment Agreement"
) with Michael Macaluso, the Company's Chief Executive Officer and principal executive officer. The Macaluso Employment Agreement supersedes and replaces the Company's prior employment agreement with Mr. Macaluso entered into on December 14, 2019. The Macaluso Employment Agreement provides for an annual base salary of $550,000 and an annual discretionary bonus of up to fifty percent (50%) of Mr. Macaluso's base salary, with the exact amount to be determined by the Compensation Committee of the Board based on achievement of individual and Company performance objectives established by the Compensation Committee. In connection with the Macaluso Employment Agreement, Mr. Macaluso was awarded 950,000 shares of restricted stock, with 150,000 shares vesting upon the effective date of the Macaluso Employment Agreement, 200,000 shares vesting on January 1, 2022 and 200,000 additional shares vesting annually each year thereafter, such that all shares of restricted stock will be fully vested on January 1, 2025.
​
If Mr. Macaluso's employment is terminated by the Company without Cause (as defined in the Macaluso Employment Agreement) or by Mr. Macaluso for Good Reason (as defined in Macaluso Employment Agreement), he
will be entitled to a lump sum severance payment equal to six months of his base salary in effect at the date of termination, less applicable withholding. In addition, the vesting and exercisability of all then outstanding options held by Mr. Macaluso will accelerate in full. Upon the occurrence of a Change in Control (as defined in the Macaluso Employment Agreement), all then outstanding stock options, restricted stock and other stock-based grants held by Mr. Macaluso will immediately and irrevocably vest and become exercisable and any restrictions thereon shall lapse.
This description of the Macaluso Employment Agreement does not purport to be complete and is subject to, and qualified in its entirety by, the full text of the Macaluso Employment Agreement,
which will be filed as an exhibit to the Company's Annual Report on Form 10-K for the year ended December 31, 2021.
Ms. Holli Cherevka
​
On October 11, 2021, the Company and Ms. Cherevka entered into the Cherevka Employment Agreement. The Cherevka Employment Agreement supersedes and replaces the Company's prior employment agreement with Ms. Cherevka entered into on September 16, 2019. The Cherevka Employment Agreement provides that Ms. Cherevka will serve as the Company's President and COO for an annual base salary of $375,000 and an annual discretionary bonus of up to fifty percent (50%) of Ms. Cherevka's base salary, with the exact amount to be determined by the Compensation Committee of the Board based on achievement of individual and Company performance objectives established by the Compensation Committee. In connection with the Cherevka Employment Agreement, Ms. Cherevka was awarded 500,000 shares of restricted stock, with 100,000 shares vesting upon the effective date of the Cherevka Employment Agreement, 100,000 shares vesting on January 1, 2022 and 100,000 additional shares vesting annually each year thereafter, such that all shares of restricted stock will be fully vested on January 1, 2025.
​
If Ms. Cherevka's employment is terminated by the Company without Cause (as defined in the Cherevka Employment Agreement) or by Ms. Cherevka for Good Reason (as defined in the Cherevka Employment Agreement), she will be entitled to a lump sum severance payment equal to six months of her base salary in effect at the date of termination, less applicable withholding. In addition, the vesting and exercisability of all then outstanding options held by Ms. Cherevka will accelerate in full. Upon the occurrence of a Change in Control (as defined in the Cherevka Employment Agreement), all then outstanding stock options, restricted stock and other stock-based grants held by Ms. Cherevka will immediately and irrevocably vest and become exercisable and any restrictions thereon shall lapse.
This description of the Cherevka Employment Agreement does not purport to be complete and is subject to, and qualified in its entirety by, the full text of the Cherevka Employment Agreement,
which will be filed as an exhibit to the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2021.
Mr. Daniel Stokely
On October 11, 2021, the Company entered into a new three-year employment agreement (the
"Stokely Employment Agreement"
) with Daniel Stokely, the Company's Chief Financial Officer and principal financial officer. The Stokely Employment Agreement supersedes and replaces the Company's prior employment agreement with Mr. Stokely entered into on July 9, 2019. The Stokely Employment Agreement provides for an annual base salary of $335,000 and an annual discretionary bonus of up to fifty percent (50%) of Mr. Stokely's base salary, with the exact amount to be determined by the Compensation Committee of the Board based on achievement of individual and Company performance objectives established by the Compensation Committee. In connection with the Stokely Employment Agreement, Mr. Stokely was awarded 335,000 shares of restricted stock, with 67,000 shares vesting upon the effective date of the Stokely Employment Agreement, 67,000 shares vesting on January 1, 2022 and 67,000 additional shares vesting annually each year thereafter, such that all shares of restricted stock will be fully vested on January 1, 2025.
​
If Mr. Stokely's employment is terminated by the Company without Cause (as defined in the Stokely Employment Agreement) or by Mr. Stokely for Good Reason (as defined in the Stokely Employment Agreement), he will be entitled to a lump sum severance payment equal to six months of his base salary in effect at the date of termination, less applicable withholding. In addition, the vesting and exercisability of all then outstanding options held by Mr. Stokely
will accelerate in full. Upon the occurrence of a Change in Control (as defined in the Stokely Employment Agreement), all then outstanding stock options, restricted stock and other stock-based grants held by Mr. Stokely will immediately and irrevocably vest and become exercisable and any restrictions thereon shall lapse.
This description of the Stokely Employment Agreement does not purport to be complete and is subject to, and qualified in its entirety by, the full text of the Stokely Employment Agreement,
which will be filed as an exhibit to the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2021.
Adoption of Indemnification Agreement
On October 13, 2021, the Board approved and adopted an updated form of indemnification agreement to be entered into by the Company with its directors, executive officers and certain other key employees (the
"Indemnification Agreement"
). The Indemnification Agreement was adopted in order to incorporate certain updates that reflect current market indemnification practices and will supersede any previous indemnification agreement entered into by the Company with the respective director, executive officer or other key employee.
​
As is the case with the Company's previous form of indemnification agreement, the Indemnification Agreement requires the Company to indemnify the counterparty, to the fullest extent permitted by law, for certain expenses, including attorneys' fees, judgments, penalties, fines and settlement amounts actually and reasonably incurred in any action or proceeding arising out of such party's status as a service provider to the Company or one of its subsidiaries or any other company or enterprise to which service is provided at the Company's request.
​
The foregoing summary and description of the provisions of the Indemnification Agreement does not purport to be complete and is subject to, and qualified in its entirety by, the full text of the Indemnification Agreement, which will be filed as an exhibit to the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2021.
​
Item 9.01
Financial Statements and Exhibits.
​
(d)    Exhibits.
​
99.1
Press release, dated October 13, 2021
104
The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.
​
​
​
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
​
AMPIO PHARMACEUTICALS, INC.
Date:  October 15, 2021
By:
/s/ Daniel G. Stokely
Name: Daniel G. Stokely
Title: Chief Financial Officer and Secretary
​
​
​
​
​